Excellent Tolerance of Rituxan When Given After Mitoxantrone-Cyclophosphamide: An Effective and Safe Combination for Indolent Non-Hodgkin’s Lymphoma

Publication
Article
OncologyONCOLOGY Vol 14 No 3
Volume 14
Issue 3

Rituximab (Rituxan) may be an ideal agent for combination with chemotherapy in patients with extensive indolent lymphoma because of non–cross-resistant efficacy and differential toxicity. However, lethal complications have occurred. Furthermore

Rituximab (Rituxan) may be an ideal agent for combination with chemotherapy in patients with extensive indolent lymphoma because of non–cross-resistant efficacy and differential toxicity. However, lethal complications have occurred. Furthermore, the potential for synergy with chemotherapy has been documented.

A total of 24 patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) have been treated with a novel, three-drug combination: cyclophosphamide (Cytoxan, Neosar), mitoxantrone (Novantrone), and rituximab. Patient characteristics included: median age, 60 years (range, 36 to 72 years); follicular histology, 13 patients; small lymphocytic lymphoma/chronic lymphocytic leukemia, 6 patients; lymphoplasmacytic, 4 patients; marginal zone, 1 patient. All 24 patients had stage III or IV disease. Of the 24 patients, 10 had received prior treatment with one to three courses of chemotherapy (including alkylating agents).

Patients first received cyclophosphamide, 800 mg/m², and mitoxantrone, 8 mg/m² intravenously [IV] on day 1, every 3 weeks for two cycles. Subsequently, patients received rituximab, 375 mg/m², followed by mitoxantrone, 8 mg/m², every 2 weeks for four cycles. The regimen, particularly rituximab, was extremely well tolerated.

Only 2 of 22 assessable patients experienced grade 1 or 2 infusion-related toxicity (mild chills, fever of 37.9 °C, or rash) during the first rituximab treatment (1 patient had received rituximab previously). Grade 4 neutropenia was noted at some point in 14 patients, who were offered granulocyte-macrophage colony-stimulating factor (GM-CSF [Leukine, Prokine]) support for improvement of neutropenia and, possibly, enhancement of antibody-dependent cellular cytotoxicity (ADCC). No infections were noted. Alopecia was minimal.

Of 21 evaluable patients, 1 had a transient partial response (PR), 2 had a sustainable PR, and 17 achieved a complete response (CR) after a median follow-up of 12 months. Hence, the overall response rate is 95%. The objective responses per subtype are: follicular, 11/11; small lymphocytic lymphoma, 4/5; plasmacytic, 4/4; and marginal zone, 1/1. Except for two patients, all responders remain in remission. Molecular remissions were noted in three of five tested patients.

CONCLUSION: We conclude that the cyclophosphamide-mitoxantrone-rituximab regimen is effective and extremely well tolerated. Furthermore, rituximab-related morbidity has not been observed.

Click here for Dr. Bruce Cheson’s commentary on this abstract.

Articles in this issue

Comparative Economic Analysis of the Treatment of Relapsed Low-Grade B-Cell Non-Hodgkin’s Lymphoma (NHL) in France Using CHOP, Fludarabine, or Rituximab
FHIT Gene, Smoking, and Cervical Cancer
Final Report on the Safety and Efficacy of Retreatment With Rituximab for Patients With Non-Hodgkins Lymphoma
Prospective, Randomized, Controlled Study of Zevalin Radioimmunotherapy Compared to Rituximab Immunotherapy for B-Cell, Non-Hodgkins Lymphoma: Interim Results
IOM Medical Error Estimates Questioned, But Legislation Considered
Less Toxic Therapies for Hodgkin’s Disease May Reduce Secondary Cancers
Preserving Fertility in Young Women With Ovarian Cancer Does Not Decrease Survival
Iodine-131 Tositumomab for Patients With Transformed, Low-Grade Non-Hodgkin’s Lymphoma: Overall Clinical Trial Experience
Survival Rates Significantly Worse For African-Americans With Endometrial Cancer
Rituximab Has Significant Activity in Patients With Chronic Lymphocytic Leukemia
Responders to Rituximab Show Continued Tumor Regression Over Time and a Progression-Free Survival That Correlates With Response Classification
PhRMA Criticizes FDA’s Proposed Rule on Antibiotic Approvals
Phase II Study of Rituximab in Combination With CHOP in Patients With Previously Untreated Intermediate- or High-Grade Non-Hodgkin’s Lymphoma
New Antibiotic Effective in Treating Gram-Positive Bacteremia
Reduced-Dose Zevalin Radioimmunotherapy for Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma Patients With Preexisting Thrombocytopenia: Report of Interim Results of a Phase II Trial
Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Related Content